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Summary
Phenylketonuria (PKU) and mild hyperphenylalanine-
mia (MHP) are allelic disorders caused by mutations in
the gene encoding phenylalanine hydroxylase (PAH).
Previous studies have suggested that the highly variable
metabolic phenotypes of PAH deficiency correlate with
PAH genotypes. We identified both causative mutations
in 686 patients from seven European centers. On the
basis of the phenotypic characteristics of 297 function-
ally hemizygous patients, 105 of the mutations were as-
signed to one of four arbitrary phenotype categories.We
proposed and tested a simple model for correlation be-
tween genotype and phenotypic outcome. The observed
phenotype matched the predicted phenotype in 79% of
the cases, and in only 5 of 184 patients was the observed
phenotype more than one category away from that ex-
pected. Among the seven contributing centers, the pro-
portion of patients for whom the observed phenotype
did not match the predicted phenotype was 4%–23%
( ), suggesting that differences in methods usedP ! .0001
for mutation detection or phenotype classification may
account for a considerable proportion of genotype-phe-
notype inconsistencies. Our data indicate that the PAH-
mutation genotype is the main determinant of metabolic
phenotype in most patients with PAH deficiency. In the
present study, the classification of 105 PAH mutations
may allow the prediction of the biochemical phenotype
in 110,000 genotypes, which may be useful for the man-
agement of hyperphenylalaninemia in newborns.
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Introduction
Deficiency of phenylalanine hydroxylase (PAH [MIM
261600]) impairs hepatic hydroxylation of phenylala-
nine to tyrosine, the major route of phenylalanine me-
tabolism in humans (Scriver et al. 1995). The disorder
is transmitted in an autosomal recessive pattern and is
the most common inborn error of amino acid metabo-
lism in the white population, with an average incidence
of 1/10,000. The key feature and marker for neonatal
detection is elevated serum concentrations of phenylal-
anine (Scriver et al. 1995).
PAH deficiency is a highly heterogeneous trait show-
ing a broad continuum of phenotypes. Complete or near-
complete deficiency of PAH activity is designated “classic
PKU” and results in profound and irreversible mental
retardation unless the dietary exposure to phenylalanine
is drastically reduced. For diagnostic and therapeutic
purposes, the continuum of milder forms has been sub-
divided into arbitrary categories, generally termed
“moderate PKU,” “mild PKU,” and “mild hyperphe-
nylalaninemia” (MHP). As in the case of classic PKU,
well-adjusted restriction of phenylalanine intake is re-
quired to ensure normal physical, neurological, and
cognitive development in patients with the milder forms
of PKU, whereas no dietary correction is required to
prevent neurological symptoms in individuals with MHP
(Gu¨ttler 1980; Scriver et al. 1995).
It is now well established that PAH deficiency is caused
by mutations in the gene encoding PAH and that the
different forms of PAH deficiency are allelic (Ledley et
al. 1986; Eisensmith and Woo 1992; Guldberg et al.
1994b). As is true of most other inherited disorders, the
genetic heterogeneity of PAH deficiency is enormous,
with 1300 different mutations now identified, world-
wide, by the PAH Mutation Analysis Consortium (No-
wacki et al. 1998). Some mutations cause complete ab-
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olition of PAH function, whereas others are associated
with residual in vitro activity in the range of 2%–70%
(Okano et al. 1991; John et al. 1992; Svensson et al.
1992; Desviat et al. 1995, 1996; Eiken et al. 1996a).
This continuous spectrum of mutation-related enzyme
activities, together with the plethora of possible muta-
tion combinations (genotypes), may explain the ob-
served interindividual heterogeneity of metabolic
phenotypes.
The capability to predict the phenotypic outcome in
newborn hyperphenylalaninemics would be highly use-
ful as a tool for refining the diagnosis and implementing
an optimal dietary therapy. Several studies have sug-
gested a simple correlation between PAH genotype and
metabolic phenotype and have reported the phenotypic
associations of particular mutation combinations (Oka-
no et al. 1991; Rey et al. 1992; Svensson et al. 1993;
Guldberg et al. 1994a; Zschocke et al. 1994; Dianzani
et al. 1995; Eiken et al. 1996b; Eisensmith et al. 1996;
Romano et al. 1996; Desviat et al. 1997; Kayaalp et al.
1997). However, three factors have hampered the es-
tablishment of a more universal system for predicting
the phenotype on the basis of genotype data: (1) the
enormous mutational heterogeneity, (2) the different
methods and criteria used for diagnosis and classifica-
tion, and (3) lack of knowledge about how the possible
interaction between two different mutant polypeptides
in the tetrameric holoenzyme may influence the phe-
notypic outcome. Herein, we have attempted to over-
come some of these limitations by analyzing a large num-
ber of patients referred to seven European centers and
by aiming at similar criteria and methods for phenotype
classification. On the basis of this compilation we have
assigned each of 105 PAH mutations to one of the four
phenotype categories, and we have proposed a general
system that allows prediction of metabolic phenotype in
the majority of mutation combinations.
Patients and Methods
Patients and Phenotypes
Seven centers in France, Italy, Belgium, Germany, and
Denmark participated in this collaborative study. Some
centers contributed patient data from several regional
treatment centers. The John F. Kennedy Institute in Den-
mark was assigned as coordinating center and was re-
sponsible for compilation of data in a relational database
(Microsoft Access software). In all patients, hyperphe-
nylalaninemia had been detected by national mass
screening programs, and PAH deficiency had been as-
sessed after exclusion of a defect in tetrahydrobiopterin
metabolism (Scriver et al. 1995). Patients were assigned
to one of four arbitrary phenotype categories, on the
basis of data on either dietary phenylalanine tolerance
(in patients with PKU) or pretreatment blood-phenyl-
alanine levels (in individuals with MHP) (Gu¨ttler 1980;
Gu¨ttler and Guldberg 1996). Patients with classic PKU
tolerate !20 mg phenylalanine/kg body wt/d (equivalent
to 250–350 mg/d), to keep blood phenylalanine values
at 300 mmol/liter; patients with moderate PKU tolerate
20–25 mg/kg body wt/d (350–400 mg/d); and patients
with mild PKU tolerate 25–50 mg/kg body wt/d
(400–600 mg/d). Phenylalanine tolerance was deter-
mined in patients 12 years of age; the majority of de-
terminations were made in children 5 years of age. Pa-
tients who have phenylalanine levels !600 mmol/liter on
a normal diet were classified as having MHP.
Genotype Data and Mutation Nomenclature
For all patients recorded in the database, two presum-
ably causative alterations in the PAH gene were iden-
tified. Genotyping was performed at the treatment center
or at the John F. Kennedy Institute. The approach for
genotyping varied among the participating centers and
was based on the use of a variety of PCR-based muta-
tion-detection assays, including diagnostic assays (e.g.,
allele-specific oligonucleotide [ASO] analysis, allele-spe-
cific PCR, and restriction-enzyme analysis), mutation-
scanning assays (e.g., SSCP, chemical cleavage analysis,
heteroduplex analysis, and denaturing gradient–gel elec-
trophoresis [DGGE]), and sequence analysis (for a recent
review of mutation-detection methods, see Nollau and
Wagener 1997). Most centers used a combination of
different techniques.
Mutations were referred to by their “trivial names,”
as registered in the PAH Mutation Analysis Consortium
Database. The corresponding systematic names, as rec-
ommended by Antonarakis (1998), are given in the da-
tabase as well. For some of the patients, associations
between genotype and various phenotypic parameters
have been reported elsewhere (Rey et al. 1992; Guldberg
et al. 1994a, 1995; Dianzani et al. 1995; Burgard et al.
1996; Romano et al. 1996). The same data may be found
in the PAH Mutation Analysis Consortium Database,
and they may have been included in a recent metanalysis
(Kayaalp et al. 1997).
Results
Mutation and Phenotype Distributions
A total of 686 patients with PAH deficiency were re-
corded in the database. The number of patients con-
tributed by each of the seven centers was 46–180. For
all patients, one criterion for inclusion was that two
presumably causative mutations in the PAH gene could
be ascertained. The 133 different mutations (listed in the
Appendix) include 87 missense mutations, 16 splice-site
mutations, 13 nonsense mutations, 10 frameshift dele-
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Figure 1 Distribution of phenotypes for the 12 PAH mutations that were found in more than one phenotype category, in functionally
hemizygous patients.
tions, 3 frameshift insertions, 2 in-frame deletions, and
2 mutations (G10G and Q304Q) that could not be un-
ambiguously classified but that may affect mRNA pro-
cessing or stability (Richard and Beckmann 1995). On
the basis of individual data on phenylalanine tolerance
and pretreatment serum phenylalanine levels, the pa-
tients were assigned to one of the four arbitrary phe-
notype categories. A total of 332 patients (48%) had
classic PKU; 95 (14%) had moderate PKU; 149 (22%)
had mild PKU; and 110 (16%) had MHP.
Classification of Mutations
We have previously suggested that the most reliable
and useful approach for the assignment of individual
PAH mutations to particular phenotype categories
would rely on patients in whom the mutant allele acts
on its own—that is, in functionally hemizygous patients
(Guldberg et al. 1995). Among the 133 different mu-
tations identified in the present study, 37 are known or
predicted to completely abolish PAH activity (Appen-
dix). The majority of these mutations are frameshift mu-
tations, splice-site mutations, and base substitutions that
introduce a premature stop codon. Base substitutions
affecting splice-site consensus regions outside the invar-
iant AG-GT dinucleotides may not completely impair
correct mRNA splicing (Krawczak et al. 1992) and, ac-
cordingly, were not classified as null mutations. The mis-
sense mutations that were considered as null mutations
have been shown to result in zero enzyme activity in
vitro. The assignment of the 37 mutations as null mu-
tations was in agreement with the general observation,
in this and previous studies, that homozygotes and ge-
netic compounds show a classic-PKU phenotype. Among
169 patients with two predefined null mutations, we
identified 7 patients who had not been diagnosed as
having classic PKU—2 IVS12nt1gra/IVS7nt1gra sib-
lings with mild PKU, 1 IVS12nt1gra homozygote with
moderate PKU, and 4 additional patients (ge-
notypes Y356X/P281L, S349P/R252W, and S349P/
IVS12nt1gra, and R408W/IVS12nt1gra) with mod-
erate PKU. Six of these patients were contributed by one
center (see below).
To assess the intrinsic severity of the remaining mu-
tations, we studied the phenotype characteristics in 297
patients who carry a putative null mutation on one of
their chromosomes and who therefore can be considered
as functionally hemizygous for the mutation on the other
chromosome. For 19 mutations, the assignment was un-
ambiguous because the phenotype classification was
consistent in two or more functionally hemizygous pa-
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Table 1
Proposed Model for Phenotypic Effect of Two Mutant PAH Alleles, Expressed as the Sum of Their AVs
PHENOTYPIC EFFECT WHEN AV OF FIRST MUTATION IS
AV OF SECOND MUTATION 1 (Classic PKU) 2 (Moderate PKU) 4 (Mild PKU) 8 (MHP)
1 (Classic PKU) 2 (Classic PKU) 3 (Moderate PKU) 5 (Mild PKU) 9 (MHP)
2 (Moderate PKU) 4 (Moderate PKU/mild PKU) 6 (Mild PKU) 10 (MHP)
4 (Mild PKU) 8 (Mild PKU/MHP) 12 (MHP)
8 (MHP) 16 (MHP)
tients. Thirty-seven mutations were found in only one
functionally hemizygous patient each, and their assign-
ment to particular phenotype categories may therefore
be somewhat uncertain. For 12 mutations, patients had
been recorded in more than one phenotype category (fig.
1). Nine of these mutations (all except R68S, L348V,
and E390G) were assigned to two categories by at least
one of the seven contributing centers. It is notable that
R261Q had been assigned to two phenotype categories
(classic PKU and moderate PKU) by five of the centers.
In all cases, the mutation was assigned to the category
in which it appeared most often. For example, the
R158Q mutation was found in 13 functionally hemi-
zygous patients diagnosed as having classic PKU and in
4 patients classified as having moderate PKU and, ac-
cordingly, was classified as a classic-PKU mutation.
On the basis of the criteria outlined above, 105 of the
mutations were assigned to one of the four phenotype
categories (Appendix). Five of the seven mutations that
were assigned to the moderate-PKU category were also
represented in at least one other phenotype category.
Among the MHP mutations, only one (E390G) was oc-
casionally found in patients with mild PKU, suggesting
that it confers a phenotype at the border between mild
PKU and MHP. On the basis of strict criteria for MHP,
E390G would be classified as a mild-PKU mutation
(Zschocke et al. 1994).
A Simple Correlation between Genotype and
Phenotype
Results from previous studies of PAH deficiency have
suggested a simple correlation between genotype and
phenotype, implying (1) that the milder of two mutations
is “quasi-dominant” and determines the phenotypic out-
come and (2) that gene dosage has a significant ef-
fect—that is, a patient homozygous for a mutation with
residual enzyme activity may exhibit a milder phenotype
than is seen in a patient carrying the mutation in the
functionally hemizygous constellation. To convert these
observations into a more formalized system, we assigned
each mutation an arbitrary assigned value (AV): AV 
, for classic-PKU mutations; , for moderate-1 AV  2
PKU mutations; , for mild-PKU mutations; andAV  4
, for MHP mutations. These values were chosenAV  8
as the lowest positive whole numbers that allow dis-
crimination between the different mutation combina-
tions. By means of this classification, the phenotype re-
sulting from the combination of two mutant PAH alleles
may be expressed numerically as the sum of the two
mutations’ AVs (table 1).
The general validity of this relatively simplistic model
was tested in 184 patients who did not carry one of the
predefined null mutations—and who therefore were not
used for mutation classification—but who were homo-
zygous or compound heterozygous for mutations of as-
signed severity (Appendix). There were 48 different mu-
tations in these patients. As shown in table 2, the
observed phenotype matched the expected phenotype in
145 (78.8%) of the patients. The lowest “concordance
rate” (44.8%) was observed for patients with expected
moderate-PKU phenotype, whereas the correlation was
virtually complete for the two groups expected to show
either an MHP phenotype or a phenotype at the border
between MHP and mild PKU.
In five patients, the observed phenotype was more
than one category away from the expected phenotype.
Four of these patients (three R158Q homozygotes and
one F299C/R158Q genetic compound with mild PKU)
were contributed by one center (see below). The re-
maining patient had the genotype IVS10nt-11gra/L48S
and was diagnosed as having classic PKU.
Possible Causes of Genotype-Phenotype
Inconsistencies
Among 650 patients carrying two mutations that had
both been classified with respect to intrinsic severity (Ap-
pendix), 88 (13.5%) had been phenotypically classified
in disagreement with the genotype-based consensus. To
address whether this relatively high number of incon-
sistencies is due to a true lack of correlation between
genotype and phenotype or may relate to intercenter
differences in methods and criteria for phenotype clas-
sification, the proportion of patients for whom the ob-
served phenotype did not exactly match the expected
phenotype was determined, for each of the seven centers.
As shown in table 3, the “inconsistency rate” was
4%–23% ( ; ). Other observations2x  28.9 P ! .0001
that may suggest a possible implication of discrepant
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Table 2
Observed versus Expected Metabolic Phenotypes in 184 Individuals with PAH Deficiency
AV1AV2
EXPECTED
PHENOTYPEa
NO. WITH OBSERVED PHENOTYPEb
PERFECT
MATCHESc
(%)
PKU
MHP TotalClassic Moderate Mild
2 Classic PKU 42* 11 4 ) 57 73.7
3 Moderate PKU 10 13* 6 ) 29 44.8
4 Moderate/mild PKU 1 6* 6* ) 13 92.3
5 and 6 Mild PKU 1 3 23* 2 29 79.3
8 Mild PKU/MHP ) ) 10* 10* 20 100
9–16 MHP ) ) 1 35* 36 97.2
Total 54 33 50 47 184
a Determined, for each patient, on the basis of the sum of the AVs of the two PAH mutations
(according to the entries in the Appendix and table 1).
b Groups in which the expected phenotype matches the observed phenotype are marked by as-
terisks (*).
c Between the observed phenotype and the expected phenotype.
procedures for phenotype classification were (1) that 6
of 10 patients for whom the observed phenotype was
more than one category away from the expected phe-
notype were contributed by one center and (2) that one
center had classified three patients homozygous for the
R158Q mutation as having mild PKU whereas another
center had classified four R158Q homozygotes as having
classic PKU.
We also addressed whether particular mutations or
mutation combinations were prevalent in the 88 patients
with discordant phenotypes. This analysis revealed an
overrepresentation of three mutations—I65T, R261Q,
and R158Q. These mutations were found in 50 (57%)
of the discordant patients, whereas they were found in
only 14% of the patients for whom there was concor-
dance between expected and observed phenotypes. We
did not, however, find any relation between the fre-
quency of these three mutations and the inconsistency
rate for the seven contributing centers; for example, the
highest proportion of patients carrying I65T, R261Q, or
R158Q on at least one chromosome was found in centers
“D” (39.5%) and “F” (34.5%), which both showed rel-
atively low inconsistency rates (table 3).
Discussion
We have compiled data on PAH-mutation genotypes
and corresponding metabolic phenotypes in 686 patients
with PAH deficiency who had been referred to seven
European centers. This has allowed us to (1) assess the
intrinsic severity of 105 PAH mutations, (2) test a simple
model for correlation between PAH genotypes and met-
abolic phenotypes of PAH deficiency, and (3) address
possible explanations for those cases in which the as-
sociation between genotype and phenotype deviates
from that expected.
The main purpose of our study was to determine
whether a simple correlation exists between PAH geno-
types and metabolic phenotypes, implying (1) that other
components of the phenylalanine homeostatic system
(reviewed by Scriver et al. 1995) contribute insignifi-
cantly to the phenylalanine-hydroxylating capacity in
patients with PAH deficiency and (2) that there are gen-
erally no relevant positive or negative interactions be-
tween two different mutant monomers in the mature
PAH tetramer (allelic complementation).
Our data provide both direct and indirect evidence
that a simple genotype-phenotype correlation does exist
in most patients with PAH deficiency. First, having as-
signed each of 68 mutations to a particular phenotype
category, on the basis of the analysis of functionally
hemizygous patients, we observed a perfect match be-
tween the expected and observed phenotypes in nearly
80% of the patients who had not been used for the
assessment of mutations. It is notable that in only 3%
of the patients was the observed phenotype more than
one category away from that expected. Second, there
was virtually complete association between genotype
and phenotype in the group of individuals presenting
with MHP in whom phenotype classification was based
solely on serum phenylalanine values and was not com-
plicated by a dietary-therapy regimen. Third, the pro-
portion of patients for whom the observed and predicted
phenotypes did not coincide differed significantly be-
tween the centers, even considering that the centers had
contributed unequal numbers of patients for mutation
classification. Other things being equal, if all genotype-
phenotype inconsistencies were real, they would be ex-
pected to be distributed equally among the participating
centers.
Taken together, these observations (1) suggest that a
significant proportion of patients may have been mis-
classified and (2) underline previous observations that
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Table 3
Patients Carrying Two PAH Mutations Who Could Be Classified, According to Data in the Appendix
NO. OF PATIENTS (RATE)
Center
TotalA B C D E F G
Total 174 50 145 41 60 55 125 650
Inconsistenta 7 (.04) 8 (.16) 33 (.23) 7 (.17) 4 (.07) 4 (.07) 25 (.25) 88
a Observed phenotype did not match expected phenotype (according to data in table 1).
genotypes and phenotypes, although exact in their na-
ture, may be difficult to accurately assess. Some of the
observed inconsistencies may be due to the inadequacy
of some mutation-detection assays, as has recently been
reported in a cystic fibrosis quality-control study (Cup-
pens and Cassiman 1995). Most centers participating in
the present study had used diagnostic assays, such as
allele-specific PCR and restriction-enzyme analysis, to
rapidly screen for the most common PAH mutations.
Since two mutations had been identified in all cases, the
majority of incorrect typings possibly relating to the use
of these methods would be due to false-positives. Alter-
natively, the use of methods, including sequencing, that
examine only parts of the PAH gene would leave double
mutant alleles undetected (Savov et al. 1995; Guldberg
et al. 1996). Nevertheless, we also noticed genotype-
phenotype inconsistencies among patients who had been
genotyped by whole-gene DGGE scanning and sequence
analysis—for example, in the case of a classic-PKU pa-
tient with genotype IVS12nt1gra/Y414C.
Other classification discrepancies may relate to the
arbitrary four-level phenotype-classification system used
here, which does not fully respect the continuum of PAH
phenotypes and which will appear inadequate for clas-
sification of phenotypes that occur at the border between
two different classes. It is noteworthy in this respect that
many of the patients with phenotypes deviating from the
majority carried mutations that have been associated
with residual in vitro activities in the range of 10%–30%
and have been assigned to the moderate-PKU category
( ). The moderate-PKU category, intermediate be-AV  2
tween classic PKU and mild PKU, has not been used
routinely by some of the participating centers and, in
general, may be difficult to assess. If moderate PKU were
excluded as a separate category and if classic PKU and
mild PKU were extended to include the phenylalanine-
tolerance levels of moderate PKU, the number of ge-
notype-phenotype inconsistencies observed in this study
would be significantly reduced.
Another interesting observation was that one of the
centers with a high inconsistency rate generally had di-
agnosed its patients as having a phenotype more severe
than would be expected on the basis of the genotype. A
closer look at the therapeutic guidelines at this center
revealed that the patients were generally kept at a lower
serum phenylalanine level than patients from the other
centers, which would cause a relatively lower phenyl-
alanine tolerance and, accordingly, a shift in genotype-
phenotype correlations. Other genotype-phenotype dis-
cordances may be due either to similar discrepancies
from the standard phenylalanine-tolerance classification
criteria—including both more or less strict adherence to
the target phenylalanine level and age of patients at the
time of testing—or to recording of phenylalanine tol-
erance in periods of growth-rate fluctuation.
Despite the different lines of evidence speaking in fa-
vor of a simple correlation between PAH genotypes and
PAH-deficiency phenotypes, we also identified a number
of cases that may not be explained by genotypic or phe-
notypic misclassifications. One example of such discrep-
ancy is the multiple phenotypic associations of the I65T
mutation. In line with previous studies (John et al. 1992;
Desviat et al. 1997; Kayaalp et al. 1997), we identified
four functionally hemizygous patients with classic PKU,
five patients with moderate PKU, and one patient with
mild PKU. A potential cause of these inconsistencies may
relate to the biological properties and functions of the
mutant protein. I65T affects a residue that may reside
in the putative regulatory phenylalanine-binding site of
PAH (Hufton et al. 1995), implying that the activity of
the enzyme may be subject to regulation by substrate
concentrations. Accordingly, the phenylalanine tolerance
in patients under treatment may depend on the target
plasma phenylalanine levels. Several of the authors of
the present article have noticed that some patients with
mild PKU (such as patients who are Y414C genetic com-
pounds) have a relatively low phenylalanine tolerance
when treated, although plasma phenylalanine levels were
only a little above the therapeutic threshold when these
patients were untreated (J. Zschocke, G.F. Hoffman, P.
Burgard, H. Schmidt, unpublished observation). We are
presently investigating the possibility that phenylalanine
levels may modulate the effect of I65T and other mu-
tations—including R261Q, R158Q, L48S, and
Y414C—that are frequently represented in discordant
genotype-phenotype associations.
In conclusion, our data lend further support to the
long-standing notion that allelic variation at the PAH
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locus is the major determinant of the metabolic phe-
notypes of PAH deficiency. They also suggest a simple
correlation between PAH genotype and metabolic PAH
deficiency phenotype, which implies (1) that disease se-
verity in most cases is determined by the least severe of
two PAH mutations and (2) that two mutations with
similar severity may confer a milder phenotype than ei-
ther of the mutations would do if it acted alone. The
general observation that phenotype in patients with PAH
deficiency may be predicted solely on the basis of prior
knowledge about the individual PAH mutations, rather
than on the basis of knowledge about the effect of spe-
cific mutation combinations, together with the classifi-
cation of 1100 mutations in the present study, may form
the basis for assessment of the phenotypic outcome in
the majority of possible mutation combinations in Cau-
casians. In some patients there are inconsistencies in the
relationship between genotype and phenotype that re-
quire further investigation, and neonatal screening and
regular monitoring of blood phenylalanine levels remain
the primary strategy for the diagnosis and treatment of
PKU. Nevertheless, mutation analysis in the newborn
with hyperphenylalaninemia can provide, at a very early
stage, additional information on the biochemical phe-
notype. This is useful for counseling of patients’ families
and for the clinical management of patients, particularly
when, because of borderline phenylalanine levels, it is
unclear whether treatment is required.
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Appendix
Assignment of PAH Mutations to Metabolic Phenotypes and AVs, Based on Phenotype
Characteristics of Functionally Hemizygous Individuals (Number of Patients/Number of Centers)
Classic PKU Moderate PKU Mild PKU MHP Unclassified
M1Va E280K (7/2) F39L (2/1)b (F39L) (1/1) A47V (1/1) G10G
Q20Xa P281La (L48S) (1/1) G46S (5/1) S87R (2/2) delF39
IVS1nt5grt (1/1) IVS7nt1graa (IVS2nt5grc) (1/1) L48S (9/2)b T92I (1/1) L41F
(F39L) (1/1) IVS7nt5gra (1/1) I65T (5/2)b T63P/H64N (1/1) R155H (1/1) S67P
(L48S) (2/2) D282N (1/1) (R68S) (1/1) (I65T) (1/1) G171A (1/1) delI94
F55L (1/1) H285Y (1/1) (R158Q) (4/1) R68S (2/2)b R176L (1/1) L98S
F55fsdelTa S295Xa E6nt-96Arg (1/1) A104D (9/3) E178G (1/1) R158W
IVS2nt5grc (3/1)b F299C (1/1) R261P (2/1)b IVS4nt-5crg (1/1) V190A (1/1) N167I
(I65T) (4/3) IVS8nt1graa R261Q (21/7)b I164T (1/1) V230I (3/1) C203Y
D84Y (1/1) IVS8nt-7arg (1/1) (L311P) (1/1) V177A (1/1) R241C (1/1) P211T
P89fsinsCa S310fsdel11bpa L348V (4/2)b R241H (1/1) V245A (7/3) G218Vc
I94S (1/1) L311P (3/2)b V388M (1/1) A246V (1/1) A300S (7/4) V245E
R111Xa F327L (1/1) (Y414C) (5/2) (R261P) (1/1) I306V (3/1) L249F
R158Q (13/5)b F331L (1/1) Y277D (1/1) T380M (1/1) M276V
I174T (2/1) Q336Xa G344S (1/1) E390G (6/3)b IVS7nt-2artc
R176Xa A342T (1/1) (E390G) (4/2) A403V (14/5) I283F
W187Xa A342fsdelGa R408Q (3/2) R413S (1/1) S303P
L194P (1/1) G346fsdelGa Y414C (43/5)b (Y414C) (1/1) Q304Q
L197fsdel22bpa G346R (2/1) D415N (5/3) A309V
Y198fsdel22bpa (L348V) (3/2) P314Hd
Y204Xa S349Pa L333Fc
Y206Xa G352R (2/1) S350Tc
E221D222fsdelAGa IVS10nt-11gra (29/7) IVS10nt3arg
S231Pa IVS10nt-3crt (2/1) P366H
G239S (1/1) IVS10nt-1graa Y386Cc
R243Q (4/3) Y356Xa D394A
R243Xa S359Xa A395G
R252G (1/1) K363fsdelGa IVS12nt2trcc
R252Q (2/2) R367fsinsCa
R252Wa A395P (2/2)
A259V (1/1) IVS11nt1graa
(R261Q) (9/5) P407fsdelCa
R261Xa R408Wa
I269N (1/1) (Y414C) (1/1)
G272Xa IVS12nt1raa
K274fsdel11bpa K452fsinsAa
a Putative null mutation.
b Also represented in other phenotype categories, although at lower frequencies. In these other categories, the mutation is
in parenthesis.
c Identified in at least one patient with classic PKU and, therefore, may be formally classified as a classic-PKU mutation.
d Identified in two functionally hemizygous patients, one of which had classic PKU and the other of which had mild PKU.
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